Results 141 to 150 of about 79,249 (245)

Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden‐High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment

Cancer Reports, Volume 9, Issue 2, February 2026.
ABSTRACT Background Pembrolizumab is approved for treating patients with advanced solid tumors exhibiting high tumor mutation burden (TMB), including pancreatic cancer. However, owing to the rarity of TMB‐high pancreatic cancer, its genetic and clinical characteristics, alongside the therapeutic effectiveness of pembrolizumab, remain unclear.
Yugo Kai, Kenji Ikezawa, Kazuhiro Kozumi, Makiko Urabe, Ryoji Takada, Takumi Kinomoto, Takanori Masumoto, Masaki Kawabata, Hiroki Kishimoto, Kana Hosokawa, Kaori Mukai, Tasuku Nakabori, Yuko Yamaguchi, Naotoshi Sugimoto, Kazuyoshi Ohkawa   +14 more
wiley   +1 more source

Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 403-413, February 2026.
Circulating tumor cells (CTCs) and tumor‐derived extracellular vesicles (tdEVs) are promising biomarkers for predicting survival and informing treatment decisions in metastatic colorectal cancer (mCRC); yet their clinical application remains limited. In this study, we analyzed CellSearch image archives from 446 patients with mCRC treated in the CAIRO2 ...
Maddalena Centanni, Afroditi Nanou, Leon W. M. M. Terstappen, Kees J. A. Punt, Frank A.W. Coumans, Mats O. Karlsson, Lena E. Friberg   +6 more
wiley   +1 more source

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Abstract Objective To explore the efficacy and safety of surufatinib in combination with anti‐PD‐1/PD‐L1 antibodies (with or without chemotherapy) in patients with advanced BTC after failure of first‐line treatment. Methods 24 patients with advanced BTC who failed first‐line treatment were admitted to our centre from March 2023 to August 2024 and ...
Xinni Chen, Feng Wang, Yuan Cheng, Mengran Cao, Kuimin Mei, Xiaoyuan Chu, Fang Dai, Xinlei Gong   +7 more
wiley   +1 more source

Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS‐wild‐type metastatic colorectal cancer treated with first‐line panitumumab plus FOLFIRI/FOLFOX: Final results of the non‐interventional study VALIDATE

International Journal of Cancer, Volume 158, Issue 3, Page 716-727, 1 February 2026.
What's new? Prognostic assessment in metastatic colorectal cancer (mCRC), which is currently based on scores derived from clinical trials, requires refinement to enhance treatment outcomes and quality of care. In this study, the authors evaluated real‐world data from the German tumor registry to prospectively validate a modified mCRC prognostic score ...
Karin Potthoff, Jens Uhlig, Lutz Jacobasch, Lothar Müller, Marcel Reiser, Rebecca de Buhr, Silke Polata, Armin Gerger, Viktor Zehrer, Arno Amann, Thomas Göhler, Laura Serrer, Jan Schröder, Dieter Semsek, Andreas Köhler, Patrick Stübs, Gerald Prager, Hans Ulrich Siebenbach, Anita Schuch, Norbert Marschner   +19 more
wiley   +1 more source

New cell lines expanding the diversity of Ewing sarcoma models

International Journal of Cancer, Volume 158, Issue 3, Page 642-655, 1 February 2026.
What's new? A chromosomal translocation between the EWSR1 and ETS genes is the key oncogenic driver in Ewing sarcoma. EWSR1::FLI1, the most frequent fusion, is subdivided into different fusion types with unclear prognostic relevance. Here, the authors describe the establishment and characterization of four new, intrinsically immortal, patient‐derived ...
Maximilian Kerkhoff, Christiane Schaefer, Wilhelm G. Dirks, Dawid Krzeciesa, Maximilian Bretschneider, Pauline R. Plaumann, Wiebke K. Guder, Arne Streitbürger, Sonja Herter, Heike Peterziel, Ina Oehme, Felina Zahnow, Thomas G. P. Grünewald, Uta Dirksen   +13 more
wiley   +1 more source

Recent Advances in Integrating Graphene into Polymeric Nanocomposite Hydrogels for Biomedical Applications

Macromolecular Bioscience, Volume 26, Issue 2, February 2026.
This review explores recent progress in graphene‐based polymeric nanocomposite hydrogels and how they enhance mechanical strength, electrical conductivity, and biocompatibility. It outlines key fabrication strategies and highlights applications in drug delivery, tissue engineering, and photothermal therapy, while also discussing the emerging role of ...
Abrar Hussain, Irum Batool, Khurram Shahzad, Syed Kumail Hussain Naqvi, Shahzaib Akhter, Ujala Zafar, Khaled Chawraba, Sang Hyun Park   +7 more
wiley   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo, Hui Liu, Yu‐Jing Song, Jian‐Hua Wang, Danfeng Liu, Zhi‐Wei Zheng, Jia‐Jun Li, Boya Li, An Song, Wei He, Lei‐Lei Yang, Shuo Wang   +11 more
wiley   +1 more source

Natural Products in Cancer Prevention and Therapy: Current Challenges and Future Directions

MedComm, Volume 7, Issue 2, February 2026.
Natural products play a pivotal role in cancer therapy. They induce cancer cell death by reprogramming four metabolic pathways while precisely targeting the tumor microenvironment and immune cells. These compounds not only leverage novel delivery systems for innovative applications but also demonstrate unique therapeutic efficacy across clinical stages:
Ruimiao Qian, Jun Ge, Ni Fan, Zheng Sun, Chengcheng Zhao, Yujiao Sun, Yingpeng Li, Yunfei Li, Hui Fu   +8 more
wiley   +1 more source

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji   +4 more
wiley   +1 more source

Complete response of a metastatic gastroesophageal adenocarcinoma on irinotecan-based chemotherapy in a dialysis patient

International Journal of Nephrology and Renovascular Disease, 2010
J Verwimp1, F Geurs1, S Ponette2, J Ponette2, J Martens3, K Bulté21Department of Medical Oncology, 2Department of Gastroenterology, 3Department of Nephrology, Regionaal Ziekenhuis Sint-Maria, Ziekenhuislaan, Halle, BelgiumAbstract: We present ...
J Verwimp, F Geurs, S Ponette, et al
doaj